Please login to the form below

Not currently logged in
Email:
Password:

Drug science

This page shows the latest Drug science news and features for those working in and with pharma, biotech and healthcare.

Pushing all the wrong buttons

Pushing all the wrong buttons

Technology was going to be the saviour. Not the technology of science and drug development which, incidentally, has been a saviour during the COVID-19 pandemic, but the ‘other’ technology.

Latest news

  • Building a brighter future for rare disease patients Building a brighter future for rare disease patients

    However, the Orphan Drug Act, passed in 1983, ushered in a new era for rare disease development. ... With cutting-edge science taking centre stage in orphan drug development, academic institutions and virtual biopharma play a central role in innovation.

  • Novartis donates malaria drug for COVID-19 clinical trials Novartis donates malaria drug for COVID-19 clinical trials

    Hydroxychloroquine is a derivative of chloroquine, and is less toxic form of the latter drug. ... According to Sun Yanrong, the deputy head of the China National Center for Biotechnology Development under the Ministry of Science and Technology, the drug

  • FDA clears SK Life Science’s anti-epileptic drug Xcopri FDA clears SK Life Science’s anti-epileptic drug Xcopri

    The safety profile of the anti-epilepsy drug does include side effects – Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) was reported among patients taking Xcopri. ... said Jeong Woo Cho, president and CEO of SK Biopharmaceuticals and SK

  • FDA will maintain the pace, vows Woodcock, but warns of skills gap FDA will maintain the pace, vows Woodcock, but warns of skills gap

    She was speaking at the SVB Leerink Therapeutics Day in Boston, and reassured the biopharma sector that the agency was still focused on accelerating the drug approval process. ... and regulation – the Office of Drug Evaluation Science (ODES).

  • Charity launches real-world medical cannabis study Charity launches real-world medical cannabis study

    Drug Science – headed by the former Chair of the Advisory Council on the Misuse of Drugs Prof David Nutt – has set up a partnership between patient groups and medical cannabis companies

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Keeping up the fight against HIV and using the lessons to tackle other threats Keeping up the fight against HIV and using the lessons to tackle other threats

    The strategy echoes its HIV heritage and continuing practice of working closely with patient groups in all aspects of drug development. ... A strong connection between science and society is vital and success is based on partnerships,” added Mr Elliott.

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    30 years, the continent has struggled to keep pace with the US, where the east and west coasts are runaway leaders in producing exciting new drug science. ... it into a drug candidate with commercial potential and taking it all the way to market with

  • The real-world data conundrum The real-world data conundrum

    This change is affecting all stakeholders. From a drug development perspective, a new data science is driving a paradigm shift in the product life cycle. ... Our best guess comes from the studies undertaken by the Tufts Center for the Study of Drug

  • When science is not enough When science is not enough

    Traditional pharma companies are all about natural science and drivers such as: ‘How can we do the most impressive natural science and develop the great drug.’ Our challenge to that is ... BEACON makes it easier for different stakeholders to

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    Our research strategy is unique; we focus on the science, not just market potential. ... Research at Novartis is centred on understanding the science of disease and drug targets and of molecular pathways that may be shared by multiple diseases.".

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • New hires at FibroGen, Saniona and Turbine New hires at FibroGen, Saniona and Turbine

    She is also a committee member of the Science Board to the US Food &Drug Administration. ... In that role, Barge oversaw the company’s acquisition of Kudos, which yielded the drug Lynparza (olaparib).

  • Bone Therapeutics strengthens board with new chairman Bone Therapeutics strengthens board with new chairman

    Thomas Lienard, chief executive officer of Bone Therapeutics, said: “Stéphenne has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector.

  • Destiny Pharma appoints new CEO Destiny Pharma appoints new CEO

    Clark will also be a member of the firm’s board of directors after spending 20 years in private and public life science companies gaining international experience in drug research and ... As we move forward, Neil’s extensive leadership experience in

  • DiCE Molecules adds Dr Richard Scheller to its board of directors DiCE Molecules adds Dr Richard Scheller to its board of directors

    truly a visionary and a distinguished leader in oncology, neuroscience, immunology and infectious disease drug development. ... out our science and bring potential drug targets into the clinic.”.

  • Keith Webber leaves FDA for Perrigo Keith Webber leaves FDA for Perrigo

    Switches regulatory agency for biopharma company. Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process. ... Prior to this, he oversaw regulation of generic medicines at the

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....